Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN011
MIFTS: 68

Adenoid Cystic Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Immune diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adenoid Cystic Carcinoma

About this section

MalaCards integrated aliases for Adenoid Cystic Carcinoma:

Name: Adenoid Cystic Carcinoma 12 12 74 20 6 15 17 71
Salivary Gland Adenoid Cystic Carcinoma 12 54 15
Cylindroma 12 20
Adenoid Cystic Carcinoma of Salivary Gland 71
Carcinoma, Adenoid Cystic 44
Eccrine Dermal Cylindroma 71
Carcinoma Adenoid Cystic 54
Adenoid Cystic Cancer 12
Adenocystic Carcinoma 20
Carcinoma, Cribriform 71
Cribriform Carcinoma 20

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases Gastrointestinal diseases Oral diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080202 DOID:4866
MeSH 44 D003528
NCIt 50 C2970
SNOMED-CT 67 11671000
UMLS 71 C0010606 C0205643 C0279751 more
Sources

Summaries for Adenoid Cystic Carcinoma

About this section
GARD : 20 Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body. Symptoms depend on the tumor's location. Salivary gland tumors may cause painless masses in the mouth or face. Tumors of the lacrimal gland may cause a bulging eye or changes in vision. Those affecting the windpipe or voice box may cause respiratory symptoms or changes in speech, respectively. Advanced tumors may cause pain and/or nerve paralysis, as ACC often spreads along the nerves. It may also spread through the bloodstream. It spreads to the lymph nodes in about 5% to 10% of cases. The cause of ACC is currently unknown. It typically does not run in families. Treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. Unfortunately, ACC is typically an aggressive form of cancer that has a poor long-term outlook.

MalaCards based summary : Adenoid Cystic Carcinoma, also known as salivary gland adenoid cystic carcinoma, is related to cervical adenoid cystic carcinoma and trachea adenoid cystic carcinoma, and has symptoms including pain An important gene associated with Adenoid Cystic Carcinoma is MYBL1 (MYB Proto-Oncogene Like 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Doxepin and Histamine have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and trachea, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An adenocarcinoma that is characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells.

Wikipedia : 74 Adenoid cystic carcinoma is a rare type of cancer that can exist in many different body sites. This... more...

Sources

Related Diseases for Adenoid Cystic Carcinoma

About this section

Diseases related to Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 666)
# Related Disease Score Top Affiliating Genes
1 cervical adenoid cystic carcinoma 33.4 NFIB MYB KRT7 KIT
2 trachea adenoid cystic carcinoma 33.3 NFIB MYB
3 breast adenoid cystic carcinoma 33.2 NFIB MYBL1 ERBB2
4 lung adenoid cystic carcinoma 33.1 NFIB MYBL1 MYB KRT7 KIT
5 cutaneous adenocystic carcinoma 32.5 NFIB MYBL1 KRT7
6 ceruminous adenocarcinoma 32.4 KRT7 KIT
7 pleomorphic adenoma 32.0 TP53 KRT7 HRAS ERBB2
8 polymorphous low-grade adenocarcinoma 32.0 NFIB MYB KIT
9 adenoma 31.8 TP53 PIK3CA KRT7 KRAS AKT1
10 mucoepidermoid carcinoma 31.6 TP53 NOTCH1 KRT7 ERBB2
11 adenocarcinoma 31.4 TP53 PTEN PIK3CA KRT7 KRAS KIT
12 salivary gland carcinoma 31.4 TP53 NFIB KRT7 KIT ERBB2 CYLD
13 myoepithelial carcinoma 31.4 TP53 PIK3CA KRT7 HRAS
14 in situ carcinoma 31.4 TP53 PTEN PIK3CA HRAS ERBB2 AKT1
15 meningioma, familial 31.4 TP53 PTEN PIK3CA CREBBP AKT1
16 pleomorphic adenoma carcinoma 31.3 TP53 NFIB ERBB2
17 cribriform carcinoma 31.3 KRT7 KIT ERBB2
18 ductal carcinoma in situ 31.2 TP53 PTEN PIK3CA ERBB2 AKT1
19 epithelial-myoepithelial carcinoma 31.2 TP53 PIK3CA KRT7 HRAS FBXW7 AKT1
20 nasopharyngeal carcinoma 31.2 TP53 PTEN PIK3CA HRAS AKT1
21 adenoid basal cell carcinoma 31.2 KRT7 KIT
22 basal cell carcinoma 31.2 TP53 PTEN NOTCH1 KRT7 KIT CYLD
23 squamous cell carcinoma 31.2 TP53 PTEN PIK3CA NOTCH1 KRT7 HRAS
24 exanthem 31.1 KRAS KIT HRAS ERBB2 AKT1
25 squamous cell carcinoma, head and neck 31.1 TP53 PTEN PIK3CA HRAS FBXW7 ERBB2
26 small cell carcinoma 31.1 TP53 PTEN KRT7 KRAS KIT ERBB2
27 papilloma 31.1 TP53 PTEN KRT7 KRAS ERBB2 AKT1
28 microglandular adenosis 31.1 TP53 KIT ERBB2
29 squamous cell papilloma 31.0 TP53 HRAS
30 cervix carcinoma 31.0 TP53 PIK3CA KRT7 ERBB2 AKT1
31 tracheal cancer 31.0 NFIB MYB
32 esophageal cancer 31.0 TP53 PTEN PIK3CA KRAS HRAS FBXW7
33 thymic carcinoma 30.9 TP53 KRT7 KIT
34 spiradenoma 30.9 TP53 KRT7 CYLD
35 neuroblastoma 30.8 TP53 PTEN PIK3CA NOTCH1 KIT HRAS
36 sweat gland cancer 30.8 TP53 KRT7 ERBB2
37 sarcoma 30.8 TP53 PIK3CA KRAS KIT HRAS AKT1
38 lung cancer susceptibility 3 30.8 TP53 PIK3CA KRT7 KRAS IDH1 HRAS
39 basal cell nevus syndrome 30.8 TP53 PTEN NOTCH1 HRAS AKT1
40 necrotizing sialometaplasia 30.8 TP53 KRT7
41 renal cell carcinoma, nonpapillary 30.7 TP53 SF3B1 PTEN PIK3CA KRT7 KIT
42 hypertrophy of breast 30.7 TP53 PIK3CA ERBB2
43 parotid gland cancer 30.7 TP53 ERBB2
44 lung squamous cell carcinoma 30.7 TP53 PTEN PIK3CA NOTCH1 KRAS HRAS
45 suppression of tumorigenicity 12 30.7 TP53 PTEN PIK3CA IDH1 HRAS ERBB2
46 kidney cancer 30.7 TP53 PTEN PIK3CA AKT1
47 peripheral nervous system disease 30.7 TP53 PTEN NOTCH1 KIT HRAS ERBB2
48 lymphoma, non-hodgkin, familial 30.7 TP53 PIK3CA NOTCH1 MYB AKT1
49 pulmonary adenocarcinoma in situ 30.6 KRAS HRAS AKT1
50 brooke-spiegler syndrome 30.6 TP53 NFIB KRT7 CYLD

Graphical network of the top 20 diseases related to Adenoid Cystic Carcinoma:



Diseases related to Adenoid Cystic Carcinoma
Sources

Symptoms & Phenotypes for Adenoid Cystic Carcinoma

About this section

UMLS symptoms related to Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.43 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.43 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.43 KRAS
4 Decreased viability GR00106-A-0 10.43 KRAS
5 Decreased viability GR00221-A-1 10.43 AKT1 CYLD HRAS KRAS PIK3CA KIT
6 Decreased viability GR00221-A-2 10.43 AKT1 CYLD HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.43 AKT1 HRAS
8 Decreased viability GR00221-A-4 10.43 AKT1 PIK3CA
9 Decreased viability GR00249-S 10.43 AKT1 CYLD
10 Decreased viability GR00301-A 10.43 CYLD KRAS KIT
11 Decreased viability GR00381-A-1 10.43 KRAS
12 Decreased viability GR00402-S-2 10.43 CYLD PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.62 NFIB
14 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.62 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.62 FBXW7
16 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.62 FBXW7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.62 BCOR NFIB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.62 FBXW7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.62 BCOR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.62 AKT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.62 KRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-28 9.62 MYB
23 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.62 NFIB
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.62 FBXW7
25 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.62 AKT1 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.62 KRAS
27 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.62 AKT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.62 BCOR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.62 AKT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-95 9.62 BCOR

MGI Mouse Phenotypes related to Adenoid Cystic Carcinoma:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 AKT1 ARID2 BCOR CREBBP CYLD ERBB2
2 growth/size/body region MP:0005378 10.47 AKT1 BCOR CREBBP CYLD ERBB2 FBXW7
3 homeostasis/metabolism MP:0005376 10.46 AKT1 ARID2 CREBBP CYLD ERBB2 FBXW7
4 cardiovascular system MP:0005385 10.44 AKT1 ARID2 BCOR CREBBP ERBB2 FBXW7
5 endocrine/exocrine gland MP:0005379 10.42 AKT1 CREBBP CYLD ERBB2 FBXW7 HRAS
6 immune system MP:0005387 10.4 AKT1 ARID2 BCOR CREBBP CYLD FBXW7
7 hematopoietic system MP:0005397 10.37 AKT1 BCOR CREBBP CYLD FBXW7 IDH1
8 mortality/aging MP:0010768 10.36 AKT1 ARID2 BCOR CREBBP CYLD ERBB2
9 embryo MP:0005380 10.34 AKT1 BCOR CREBBP ERBB2 FBXW7 KIT
10 integument MP:0010771 10.32 AKT1 CREBBP CYLD ERBB2 FBXW7 HRAS
11 digestive/alimentary MP:0005381 10.31 CREBBP CYLD ERBB2 FBXW7 HRAS KIT
12 craniofacial MP:0005382 10.23 CREBBP ERBB2 FBXW7 HRAS KIT KRAS
13 muscle MP:0005369 10.11 AKT1 ARID2 CREBBP ERBB2 HRAS KIT
14 neoplasm MP:0002006 10.1 AKT1 CREBBP CYLD ERBB2 FBXW7 HRAS
15 nervous system MP:0003631 10.1 AKT1 BCOR CREBBP ERBB2 FBXW7 HRAS
16 liver/biliary system MP:0005370 10.09 AKT1 CREBBP FBXW7 KIT KRAS MYB
17 limbs/digits/tail MP:0005371 10 CREBBP CYLD ERBB2 KIT KRAS PTEN
18 normal MP:0002873 9.97 AKT1 CREBBP CYLD ERBB2 FBXW7 HRAS
19 respiratory system MP:0005388 9.77 AKT1 CREBBP CYLD ERBB2 FBXW7 HRAS
20 skeleton MP:0005390 9.4 AKT1 CREBBP ERBB2 HRAS IDH1 KIT
Sources

Drugs & Therapeutics for Adenoid Cystic Carcinoma

About this section

Drugs for Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
2
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
3
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
4
Promethazine Approved, Investigational Phase 3 60-87-7 4927
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
7 Hypnotics and Sedatives Phase 3
8 Neurotransmitter Agents Phase 3
9 Antidepressive Agents Phase 3
10 Psychotropic Drugs Phase 3
11
Histamine Phosphate Phase 3 51-74-1 65513
12 Histamine Antagonists Phase 3
13 Antidepressive Agents, Tricyclic Phase 3
14 Anesthetics Phase 3
15 Narcotics Phase 3
16 Analgesics, Opioid Phase 3
17 Analgesics Phase 3
18 Anesthetics, Intravenous Phase 3
19 Anesthetics, General Phase 3
20
Gemcitabine Approved Phase 2 95058-81-4 60750
21
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
22
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
23
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
24
Nelfinavir Approved Phase 2 159989-64-7 64143
25
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
26
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
27
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
28
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
29
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
30
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
31
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
32
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
33
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
34
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
35
Pembrolizumab Approved Phase 2 1374853-91-4
36
Etoposide Approved Phase 2 33419-42-0 36462
37
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
38
Lenvatinib Approved, Investigational Phase 2 417716-92-8
39
nivolumab Approved Phase 2 946414-94-4
40
Ipilimumab Approved Phase 2 477202-00-9
41
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
42
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
43
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
44
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
45
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538 444795
46 Immunosuppressive Agents Phase 2
47 Anti-Infective Agents Phase 2
48 Antiviral Agents Phase 2
49 Imatinib Mesylate Phase 2 220127-57-1 123596
50 Radiopharmaceuticals Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study Unknown status NCT01192087 Phase 1, Phase 2 Cetuximab
4 Phase II Study of Apatinib Mesylate Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Unknown status NCT02775370 Phase 2 Apatinib Mesylate
5 A Phase II Randomized Trial of Efficacy and Safety of Particle Therapy With or Without Apatinib as Induction Therapy for Treatment of Head and Neck Adenoid Cystic Carcinoma Unknown status NCT02942693 Phase 2 Apatinib
6 Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma Unknown status NCT02859012 Phase 2 Axitinib
7 Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT Unknown status NCT00180921 Phase 2 Imatinib
8 Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Unknown status NCT02883374 Phase 2 Chidamide
9 Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
10 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
11 A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas Completed NCT00045669 Phase 2 imatinib mesylate
12 A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
13 Gemcitabine for Advanced Salivary Cancer: A Phase II Study Completed NCT00003744 Phase 2 gemcitabine
14 Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas Completed NCT00004163 Phase 2 Trastuzumab
15 A Phase II Trial of the HIV Protease Inhibitor Nelfinavir in Patients With Recurrent Symptomatic Adenoid Cystic Cancers of the Head and Neck Completed NCT01065844 Phase 2 Nelfinavir
16 Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Head and Neck Adenoid Cystic Carcinoma Completed NCT00581360 Phase 2 doxorubicin and bortezomib
17 Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
18 Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma Completed NCT01417143 Phase 2 TKI258 (Dovitinib):
19 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Completed NCT01175980 Phase 2 Vorinostat
20 Phase II Study of RAD001monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma Completed NCT01152840 Phase 2 RAD001
21 A Phase II Study of Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01558661 Phase 2 AG-013736 (AXITINIB)
22 A Phase II Pilot Study of Dovitinib (TKI258) in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Completed NCT01524692 Phase 2 Dovitinib (TKI258)
23 A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
24 A Phase II Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma Completed NCT03999684 Phase 2 Tretinoin
25 A Phase 2 Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
26 A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE) Completed NCT01678105 Phase 2 Dovitinib
27 Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract Completed NCT02860936 Phase 2 Lenvatinib
28 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
29 Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors Completed NCT00859937 Phase 2 Dasatinib
30 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
31 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
32 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
33 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
34 A Phase 2 Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC) Recruiting NCT03990571 Phase 2 Avelumab;Axitinib
35 A Phase II Study of Lenvatinib Plus Pembrolizumab in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Recruiting NCT04209660 Phase 2 Lenvatinib;Pembrolizumab
36 Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation Recruiting NCT04214366 Phase 2
37 A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations Recruiting NCT03691207 Phase 2 AL101
38 A Prospective, Open-label, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of All-trans Retinoic Acid (ATRA) in the Treatment of Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Recruiting NCT04433169 Phase 2 All-trans Retinoic Acid;VEGFR inhibitor;Chemotherapy
39 Chidamide Combined With Cisplatin in Recurrent or Metastatic Head and Neck Adenoid Cystic Carcinoma: A Prospective, Open-label, Phase II Study of a Single Center Recruiting NCT03639168 Phase 2 Chidamide combined with cisplatin
40 Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study. Recruiting NCT04291300 Phase 2 Lutetium-177-PSMA-I&T
41 A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway Recruiting NCT03422679 Phase 1, Phase 2 CB-103
42 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
43 A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) of All Anatomic Sites of Origin Recruiting NCT04119453 Phase 2 Rivoceranib
44 A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT03087019 Phase 2 Pembrolizumab
45 A Phase II, Single-Arm Trial Assessing Local Control of Near Total Endoscopic Resection Followed by Concurrent Chemotherapy and Proton Radiation in the Treatment of Unresectable Sinonasal Tumors Active, not recruiting NCT03274414 Phase 2 Cisplatin;cisplatin and etoposide
46 The Efficacy of Cabozantinib in Advanced SAlivary Gland Cancer Patients, a Phase II Clinical Trial Active, not recruiting NCT03729297 Phase 2 Cabozantinib
47 A Phase II Study of Lenvatinib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT02780310 Phase 2 Lenvatinib
48 A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT02098538 Phase 2 Regorafenib
49 Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland Active, not recruiting NCT03146650 Phase 2
50 Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Patients With Locally Advanced, Incurable, Salivary Gland Cancers Terminated NCT00101075 Phase 2 Capecitabine;Oxaliplatin

Search NIH Clinical Center for Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Sources

Genetic Tests for Adenoid Cystic Carcinoma

About this section
Sources

Anatomical Context for Adenoid Cystic Carcinoma

About this section

MalaCards organs/tissues related to Adenoid Cystic Carcinoma:

40
Salivary Gland, Breast, Trachea, Cervix, Tongue, Skin, Prostate
Sources

Publications for Adenoid Cystic Carcinoma

About this section

Articles related to Adenoid Cystic Carcinoma:

(show top 50) (show all 4691)
# Title Authors PMID Year
1
Genetic Characterization of Adenoid Cystic Carcinoma of the Minor Salivary Glands: A Potential Familial Occurrence in First-Degree Relatives. 61 20
28210977 2017
2
C-kit gene mutations in adenoid cystic carcinoma are rare. 61 54
20514080 2010
3
Expression of c-kit and Slug correlates with invasion and metastasis of salivary adenoid cystic carcinoma. 61 54
20219417 2010
4
Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. 61 54
19877114 2010
5
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). 54 61
19574086 2009
6
Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. 54 61
19617878 2009
7
Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. 61 54
19659475 2009
8
Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. 61 54
18983466 2008
9
Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. 54 61
17936671 2008
10
[Effects of basic fibroblast growth factor on the proliferation of human salivary adenoid cystic carcinoma cell line ACC-2 and extracellular signal-regulated kinase, Cyclin D1, p2waf/cip1 signaling pathway]. 61 54
18605443 2008
11
Effect of exogenous bFGF on the proliferation of human adenoid cystic carcinoma ACC-2 cells. 54 61
18481005 2008
12
Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. 61 54
18084258 2008
13
[Prognostic value of immunohistochemistry in salivary gland cancer]. 61 54
18214402 2008
14
Expression of neural cell adhesion molecule in salivary adenoid cystic carcinoma and its correlation with perineural invasion. 61 54
17982624 2007
15
Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. 54 61
17932891 2007
16
[Expression and significance of E-cadherin in adenoid cystic carcinoma of the salivary glands]. 54 61
17927866 2007
17
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. 54 61
17761983 2007
18
Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. 54 61
16996782 2007
19
Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. 61 54
17391298 2007
20
[Effect of mechanical stimulation on the expression of E-cadherin/cateninin complex in salivary adenoid cystic carcinoma]. 61 54
17375572 2007
21
Application of alpha-smooth muscle actin and c-kit in the differential diagnosis of adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. 54 61
16807072 2007
22
A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. 61 54
16757202 2007
23
Adenoid cystic carcinoma of the buccal vestibule: A case report and review of the literature. 61 54
16996786 2006
24
[Expression of Pin1, beta-catenin and cyclin D1 in salivary adenoid cystic carcinoma and its significance]. 61 54
17129455 2006
25
Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers. 54 61
16810311 2006
26
Aberrant expression of beta-catenin, Pin1 and cylin D1 in salivary adenoid cystic carcinoma: relation to tumor proliferation and metastasis. 54 61
16865250 2006
27
Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. 61 54
16636670 2006
28
Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. 61 54
16094606 2006
29
Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. 61 54
16184379 2006
30
Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. 61 54
16140564 2006
31
KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. 61 54
16258515 2005
32
Induction of apoptosis in human salivary gland tumor cells by anti-NCAM antibody. 54 61
16211277 2005
33
Clinical prognostic factors in malignant parotid gland tumors. 61 54
16274796 2005
34
Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. 54 61
16243805 2005
35
Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. 61 54
16054424 2005
36
Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. 61 54
15846389 2005
37
Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. 61 54
16135502 2005
38
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. 54 61
16082245 2005
39
Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. 61 54
15959912 2005
40
[Expression and significance of cyclin D1 in human adenoid cystic carcinoma]. 54 61
16078452 2005
41
Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast. 61 54
15899777 2005
42
Expression of IgSF in salivary adenoid cystic carcinoma and its relationship with invasion and metastasis. 61 54
15817073 2005
43
Adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of minor salivary glands: a comparative immunohistochemical study using the epithelial membrane and carcinoembryonic antibodies. 61 54
15888109 2005
44
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. 54 61
15863127 2005
45
Expression of beta-catenin, E-cadherin and cyclin D1 in adenoid cystic carcinoma of the salivary gland. 61 54
15943036 2005
46
P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. 54 61
15792122 2005
47
"Parapharyngeal space" tumors: a cytopathological study of 24 cases on fine-needle aspiration. 54 61
15584054 2005
48
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. 61 54
15659505 2005
49
Cyclin D1 expression does not effect cell proliferation in adenoid cystic carcinoma of the salivary gland. 54 61
14714130 2004
50
Lip cancer experience in Mexico. An 11-year retrospective study. 54 61
15509490 2004
Sources

Variations for Adenoid Cystic Carcinoma

About this section

ClinVar genetic disease variations for Adenoid Cystic Carcinoma:

6 (show top 50) (show all 59)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KRAS NM_004985.5(KRAS):c.34G>C (p.Gly12Arg) SNV Pathogenic 12579 rs121913530 12:25398285-25398285 12:25245351-25245351
2 MYB t(6;9)(q23.3;p22.3) Translocation Pathogenic 495138 6:135515857-135515858
3 MYB t(6;9)(q23.3;p22.3) Translocation Pathogenic 495139 6:135516358-135516359
4 MYBL1 t(8;9)(q13.1;p22.3) Translocation Pathogenic 495136 8:67501293-67501294
5 MYB t(6;9)(q23.3;p22.3) Translocation Pathogenic 495140 6:135516423-135516424
6 MYB t(6;9)(q23.3;p22.3) Translocation Pathogenic 495137 6:135522688-135522689
7 BCOR NM_001123385.2(BCOR):c.4063G>T (p.Glu1355Ter) SNV Likely pathogenic 495127 rs780712297 X:39922109-39922109 X:40062856-40062856
8 ARID2 NM_152641.4(ARID2):c.2989C>T (p.Gln997Ter) SNV Likely pathogenic 495130 rs1555155110 12:46244895-46244895 12:45851112-45851112
9 NOTCH1 NM_017617.5(NOTCH1):c.4045_4052del (p.Ala1349fs) Deletion Likely pathogenic 495129 rs1554728034 9:139400296-139400303 9:136505844-136505851
10 BCOR NM_001123385.2(BCOR):c.4787_4802del (p.Gly1596fs) Deletion Likely pathogenic 495132 rs1555913337 X:39913526-39913541 X:40054273-40054288
11 NOTCH1 NM_017617.5(NOTCH1):c.2825G>A (p.Cys942Tyr) SNV Likely pathogenic 495128 rs1554728658 9:139404329-139404329 9:136509877-136509877
12 BCOR NM_001123385.2(BCOR):c.398_399insAC (p.Ala134fs) Insertion Likely pathogenic 495125 rs1555919960 X:39934200-39934201 X:40074947-40074948
13 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
14 FBXW7 NM_001349798.2(FBXW7):c.1393C>T (p.Arg465Cys) SNV Likely pathogenic 376414 rs867384286 4:153249385-153249385 4:152328233-152328233
15 FBXW7 NM_001349798.2(FBXW7):c.1394G>A (p.Arg465His) SNV Likely pathogenic 376415 rs1057519895 4:153249384-153249384 4:152328232-152328232
16 FBXW7 NM_001349798.2(FBXW7):c.1394G>T (p.Arg465Leu) SNV Likely pathogenic 376417 rs1057519895 4:153249384-153249384 4:152328232-152328232
17 CREBBP NM_004380.3(CREBBP):c.4336C>G (p.Arg1446Gly) SNV Likely pathogenic 376388 rs398124146 16:3788618-3788618 16:3738617-3738617
18 CREBBP NM_004380.3(CREBBP):c.4337G>T (p.Arg1446Leu) SNV Likely pathogenic 376386 rs1057519884 16:3788617-3788617 16:3738616-3738616
19 PIK3CA NM_006218.4(PIK3CA):c.1258T>C (p.Cys420Arg) SNV Likely pathogenic 31945 rs121913272 3:178927980-178927980 3:179210192-179210192
20 TP53 NM_001276697.2(TP53):c.-27C>G SNV Likely pathogenic 376641 rs28934874 17:7578479-7578479 17:7675161-7675161
21 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser) SNV Likely pathogenic 12370 rs28934874 17:7578479-7578479 17:7675161-7675161
22 CREBBP NM_004380.3(CREBBP):c.4337G>A (p.Arg1446His) SNV Likely pathogenic 376387 rs1057519884 16:3788617-3788617 16:3738616-3738616
23 FBXW7 NM_001349798.2(FBXW7):c.1394G>C (p.Arg465Pro) SNV Likely pathogenic 376416 rs1057519895 4:153249384-153249384 4:152328232-152328232
24 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys) SNV Likely pathogenic 95047 rs398124146 16:3788618-3788618 16:3738617-3738617
25 FBXW7 NM_001349798.2(FBXW7):c.1393C>G (p.Arg465Gly) SNV Likely pathogenic 376418 rs867384286 4:153249385-153249385 4:152328233-152328233
26 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
27 TP53 NM_001276697.2(TP53):c.-26C>G SNV Likely pathogenic 376640 rs1057520000 17:7578478-7578478 17:7675160-7675160
28 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
29 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Likely pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
30 IDH1 NM_001282386.1(IDH1):c.394C>A (p.Arg132Ser) SNV Likely pathogenic 375893 rs121913499 2:209113113-209113113 2:208248389-208248389
31 PIK3CA NM_006218.4(PIK3CA):c.1035T>A (p.Asn345Lys) SNV Likely pathogenic 376050 rs121913284 3:178921553-178921553 3:179203765-179203765
32 PIK3CA NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val) SNV Likely pathogenic 376485 rs1057519936 3:178952072-178952072 3:179234284-179234284
33 SF3B1 NM_012433.3(SF3B1):c.1873C>G (p.Arg625Gly) SNV Likely pathogenic 376536 rs775623976 2:198267484-198267484 2:197402760-197402760
34 IDH1 NM_001282386.1(IDH1):c.394C>G (p.Arg132Gly) SNV Likely pathogenic 375892 rs121913499 2:209113113-209113113 2:208248389-208248389
35 TP53 NM_000546.5(TP53):c.637C>G (p.Arg213Gly) SNV Likely pathogenic 376651 rs397516436 17:7578212-7578212 17:7674894-7674894
36 IDH1 NM_001282386.1(IDH1):c.395G>A (p.Arg132His) SNV Likely pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
37 TP53 NM_000546.5(TP53):c.451C>A (p.Pro151Thr) SNV Likely pathogenic 12369 rs28934874 17:7578479-7578479 17:7675161-7675161
38 PIK3CA NM_006218.4(PIK3CA):c.1258T>G (p.Cys420Gly) SNV Likely pathogenic 376469 rs121913272 3:178927980-178927980 3:179210192-179210192
39 TP53 NM_000546.5(TP53):c.638G>C (p.Arg213Pro) SNV Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
40 IDH1 NM_001282386.1(IDH1):c.394C>T (p.Arg132Cys) SNV Likely pathogenic 375891 rs121913499 2:209113113-209113113 2:208248389-208248389
41 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr) SNV Likely pathogenic 376486 rs1057519937 3:178952073-178952073 3:179234285-179234285
42 PIK3CA NM_006218.4(PIK3CA):c.1033A>C (p.Asn345His) SNV Likely pathogenic 376490 rs1057519939 3:178921551-178921551 3:179203763-179203763
43 SF3B1 NM_012433.3(SF3B1):c.1874G>A (p.Arg625His) SNV Likely pathogenic 376534 rs1057519961 2:198267483-198267483 2:197402759-197402759
44 TP53 NM_000546.5(TP53):c.638G>T (p.Arg213Leu) SNV Likely pathogenic 376650 rs587778720 17:7578211-7578211 17:7674893-7674893
45 PIK3CA NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile) SNV Likely pathogenic 179173 rs121913283 3:178952074-178952074 3:179234286-179234286
46 PIK3CA NM_006218.4(PIK3CA):c.1034A>C (p.Asn345Thr) SNV Likely pathogenic 376489 rs1057519938 3:178921552-178921552 3:179203764-179203764
47 SF3B1 NM_012433.3(SF3B1):c.1873C>T (p.Arg625Cys) SNV Likely pathogenic 376535 rs775623976 2:198267484-198267484 2:197402760-197402760
48 PIK3CA NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile) SNV Likely pathogenic 376488 rs1057519938 3:178921552-178921552 3:179203764-179203764
49 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu) SNV Likely pathogenic 376487 rs1057519936 3:178952072-178952072 3:179234284-179234284
50 TP53 NM_000546.5(TP53):c.452C>A (p.Pro151His) SNV Likely pathogenic 376639 rs1057520000 17:7578478-7578478 17:7675160-7675160

Cosmic variations for Adenoid Cystic Carcinoma:

9 (show top 50) (show all 37549)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM131674386 WASF2 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.15G>T p.T5= 1:27428876-27428876 12
2 COSM143041461 WASF2 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.15G>T p.T5= 1:27428876-27428876 12
3 COSM148982261 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
4 COSM151513835 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
5 COSM102618829 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
6 COSM87028709 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
7 COSM101181362 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2255C>T p.A752V 16:2074246-2074246 12
8 COSM151371079 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
9 COSM147692833 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
10 COSM136618137 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2435C>T p.A812V 16:2074246-2074246 12
11 COSM150576172 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
12 COSM149802491 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
13 COSM150314621 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
14 COSM110103993 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2291C>T p.A764V 16:2074246-2074246 12
15 COSM90404312 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
16 COSM151748035 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
17 COSM150355398 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 12
18 COSM151333958 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 12
19 COSM148034383 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2666T>A p.V889D 9:132897552-132897552 12
20 COSM150536749 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2531T>A p.V844D 9:132897552-132897552 12
21 COSM133086949 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2531T>A p.V844D 9:132897552-132897552 12
22 COSM149039376 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2681T>A p.V894D 9:132897552-132897552 12
23 COSM147983098 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2681T>A p.V894D 9:132897552-132897552 12
24 COSM85719495 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 12
25 COSM111040676 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 12
26 COSM150677254 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2669T>A p.V890D 9:132897552-132897552 12
27 COSM151875081 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 12
28 COSM84855029 TRPV5 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.554A>G p.H185R 7:142929054-142929054 12
29 COSM110312003 TRPV5 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.554A>G p.H185R 7:142929054-142929054 12
30 COSM113659175 TP53BP1 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.3869C>G p.T1290S 15:43422086-43422086 12
31 COSM99562983 TP53BP1 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.3869C>G p.T1290S 15:43422086-43422086 12
32 COSM99625361 TP53BP1 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.3869C>G p.T1290S 15:43422086-43422086 12
33 COSM86842324 TP53BP1 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.3854C>G p.T1285S 15:43422086-43422086 12
34 COSM143944858 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.109C>T p.R37* 17:7674945-7674945 12
35 COSM144019757 TP53 salivary gland,minor,carcinoma,adenocarcinoma c.742G>T p.D248Y 17:7674188-7674188 12
36 COSM106059381 TP53 salivary gland,minor,carcinoma,adenocarcinoma c.775G>T p.D259Y 17:7674188-7674188 12
37 COSM144653059 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.310G>A p.V104M 17:7675185-7675185 12
38 COSM142561802 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.310G>A p.V104M 17:7675185-7675185 12
39 COSM121877621 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.190C>T p.R64* 17:7674945-7674945 12
40 COSM87905712 TP53 salivary gland,minor,carcinoma,adenocarcinoma c.775G>T p.D259Y 17:7674188-7674188 12
41 COSM142838067 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.586C>T p.R196* 17:7674945-7674945 12
42 COSM106054364 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.586C>T p.R196* 17:7674945-7674945 12
43 COSM122735020 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.190C>T p.R64* 17:7674945-7674945 12
44 COSM112255102 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.427G>A p.V143M 17:7675185-7675185 12
45 COSM111765171 TP53 salivary gland,minor,carcinoma,adenocarcinoma c.775G>T p.D259Y 17:7674188-7674188 12
46 COSM142842148 TP53 salivary gland,minor,carcinoma,adenocarcinoma c.775G>T p.D259Y 17:7674188-7674188 12
47 COSM122735247 TP53 salivary gland,major,carcinoma,adenoid cystic carcinoma c.319A>G p.N107D 17:7674248-7674248 12
48 COSM112259562 TP53 salivary gland,minor,carcinoma,adenocarcinoma c.775G>T p.D259Y 17:7674188-7674188 12
49 COSM144658124 TP53 salivary gland,minor,carcinoma,adenocarcinoma c.658G>T p.D220Y 17:7674188-7674188 12
50 COSM144315359 TP53 salivary gland,minor,carcinoma,adenocarcinoma c.658G>T p.D220Y 17:7674188-7674188 12

Copy number variations for Adenoid Cystic Carcinoma from CNVD:

7 (show top 50) (show all 209)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13805 1 1 61300000 Deletion Adenoid cystic carcinoma
2 31809 1 31200000 32688000 Loss ADGRB2 Adenoid cystic carcinoma
3 31810 1 31200000 32688000 Loss EIF3I Adenoid cystic carcinoma
4 31811 1 31200000 32688000 Loss FABP3 Adenoid cystic carcinoma
5 31812 1 31200000 32688000 Loss HDAC1 Adenoid cystic carcinoma
6 31813 1 31200000 32688000 Loss IQCC Adenoid cystic carcinoma
7 31814 1 31200000 32688000 Loss KHDRBS1 Adenoid cystic carcinoma
8 31815 1 31200000 32688000 Loss LCK Adenoid cystic carcinoma
9 31816 1 31200000 32688000 Loss MARCKSL1 Adenoid cystic carcinoma
10 31817 1 31200000 32688000 Loss PTP4A2 Adenoid cystic carcinoma
11 31818 1 31200000 32688000 Loss PUM1 Adenoid cystic carcinoma
12 31819 1 31200000 32688000 Loss RBBP4 Adenoid cystic carcinoma
13 31820 1 31200000 32688000 Loss SERINC2 Adenoid cystic carcinoma
14 31821 1 31200000 32688000 Loss TXLNA Adenoid cystic carcinoma
15 33928 1 50618000 52179000 Loss CDKN2C Adenoid cystic carcinoma
16 33929 1 50618000 52179000 Loss EPS15 Adenoid cystic carcinoma
17 33930 1 50618000 52179000 Loss FAF1 Adenoid cystic carcinoma
18 33931 1 50618000 52179000 Loss NRDC Adenoid cystic carcinoma
19 33932 1 50618000 52179000 Loss RAB3B Adenoid cystic carcinoma
20 33933 1 50618000 52179000 Loss RNF11 Adenoid cystic carcinoma
21 50143 11 114500000 121200000 Deletion Adenoid cystic carcinoma
22 50146 11 114500000 121200000 Gain Salivary gland adenoid cystic carcinoma
23 58545 11 68400000 70400000 Deletion Adenoid cystic carcinoma
24 58546 11 68400000 70400000 Gain Salivary gland adenoid cystic carcinoma
25 61970 12 103800000 109000000 LOH Adenoid cystic carcinoma
26 64283 12 125900000 133851895 LOH Adenoid cystic carcinoma
27 67068 12 35800000 133851895 Loss Adenoid cystic carcinoma
28 67236 12 38200000 58100000 Deletion Adenoid cystic carcinoma
29 67639 12 43743000 50676000 Loss ACVR1B Adenoid cystic carcinoma
30 67640 12 43743000 50676000 Loss ACVRL1 Adenoid cystic carcinoma
31 67641 12 43743000 50676000 Loss ADCY6 Adenoid cystic carcinoma
32 67642 12 43743000 50676000 Loss AMIGO2 Adenoid cystic carcinoma
33 67643 12 43743000 50676000 Loss ANP32D Adenoid cystic carcinoma
34 67644 12 43743000 50676000 Loss ARF3 Adenoid cystic carcinoma
35 67645 12 43743000 50676000 Loss ATF1 Adenoid cystic carcinoma
36 67646 12 43743000 50676000 Loss CCNT1 Adenoid cystic carcinoma
37 67647 12 43743000 50676000 Loss COL2A1 Adenoid cystic carcinoma
38 67648 12 43743000 50676000 Loss DDX23 Adenoid cystic carcinoma
39 67649 12 43743000 50676000 Loss FAIM2 Adenoid cystic carcinoma
40 67650 12 43743000 50676000 Loss HDAC7 Adenoid cystic carcinoma
41 67651 12 43743000 50676000 Loss LALBA Adenoid cystic carcinoma
42 67652 12 43743000 50676000 Loss LETMD1 Adenoid cystic carcinoma
43 67653 12 43743000 50676000 Loss LIMA1 Adenoid cystic carcinoma
44 67654 12 43743000 50676000 Loss KMT2D Adenoid cystic carcinoma
45 67655 12 43743000 50676000 Loss PFKM Adenoid cystic carcinoma
46 67656 12 43743000 50676000 Loss PLEKHA8P1 Adenoid cystic carcinoma
47 67657 12 43743000 50676000 Loss PRKAG1 Adenoid cystic carcinoma
48 67658 12 43743000 50676000 Loss RACGAP1 Adenoid cystic carcinoma
49 67659 12 43743000 50676000 Loss RAPGEF3 Adenoid cystic carcinoma
50 67660 12 43743000 50676000 Loss RHEBL1 Adenoid cystic carcinoma
Sources

Expression for Adenoid Cystic Carcinoma

About this section
Search GEO for disease gene expression data for Adenoid Cystic Carcinoma.
Sources

Pathways for Adenoid Cystic Carcinoma

About this section

Pathways related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.13 TP53 PTEN PIK3CA KRAS KIT IDH1
2
ERK Signaling 63
Show member pathways
 13.92 TP53 PTEN NOTCH1 KRAS KIT HRAS
3
Gene Expression 65
Show member pathways
 13.9 TP53 SF3B1 PTEN NOTCH1 NFIB MYBL1
4
HIV Life Cycle 65
Show member pathways
 13.81 PIK3CA NOTCH1 KRAS KIT IDH1 HRAS
5
TGF-Beta Pathway 63
Show member pathways
 13.63 TP53 PIK3CA KRAS KIT HRAS ERBB2
6
Developmental Biology 65
Show member pathways
 13.6 PIK3CA NOTCH1 KRT7 KRAS KIT HRAS
7
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.55 TP53 PTEN PIK3CA KRAS KIT HRAS
8
Cytokine Signaling in Immune system 65
Show member pathways
 13.45 TP53 PIK3CA KRAS KIT HRAS ERBB2
9
CREB Pathway 63
Show member pathways
 13.41 PTEN KRAS KIT HRAS ERBB2 CREBBP
10
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.4 TP53 PIK3CA MYB KRAS HRAS CREBBP
11
PAK Pathway 63
Show member pathways
 13.4 PTEN NOTCH1 KRAS KIT HRAS ERBB2
12
IL-2 Pathway 63
Show member pathways
 13.31 TP53 PTEN KRAS HRAS ERBB2 CREBBP
13
GAB1 signalosome 65
Show member pathways
 13.2 TP53 PTEN PIK3CA KIT ERBB2 AKT1
14
TNFR1 Pathway 63
Show member pathways
 13.18 TP53 PTEN PIK3CA KRAS HRAS CREBBP
15
Phospholipase-C Pathway 63
Show member pathways
 13.17 TP53 PTEN KRAS KIT HRAS CREBBP
16
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.16 TP53 PIK3CA KRAS HRAS CYLD CREBBP
17
Human cytomegalovirus infection 36
Show member pathways
 13.04 TP53 PIK3CA KRAS HRAS CREBBP AKT1
18
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 13 PTEN PIK3CA KRAS HRAS ERBB2 AKT1
19
Focal Adhesion 36 1
Show member pathways
 13 PTEN PIK3CA KRAS HRAS ERBB2 AKT1
20
NFAT and Cardiac Hypertrophy 63
Show member pathways
 12.97 PTEN PIK3CA KRAS HRAS ERBB2 CREBBP
21
Development Angiotensin activation of ERK 23
Show member pathways
 12.93 PIK3CA KRAS KIT HRAS AKT1
22
Endometrial cancer 36
Show member pathways
 12.88 TP53 PTEN PIK3CA KRAS KIT HRAS
23
MAPK signaling pathway 36 1
12.87 TP53 KRAS KIT HRAS ERBB2 AKT1
24
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.86 PTEN PIK3CA KRAS HRAS AKT1
25
PI3K-Akt signaling pathway 36
Show member pathways
 12.83 TP53 PTEN PIK3CA NOTCH1 MYB KRAS
26
Ras signaling pathway 36
Show member pathways
 12.82 PIK3CA KRAS KIT HRAS AKT1
27
Development HGF signaling pathway 23
Show member pathways
 12.82 TP53 PTEN PIK3CA KRAS HRAS ERBB2
28
Apoptosis Modulation and Signaling 1
Show member pathways
 12.8 TP53 PIK3CA KRAS HRAS AKT1
29
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.79 TP53 PTEN PIK3CA KRAS KIT HRAS
30
Relaxin signaling pathway 36
Show member pathways
 12.77 PIK3CA KRAS HRAS CREBBP AKT1
31
4-1BB Pathway 63
Show member pathways
 12.76 TP53 KRAS HRAS CREBBP AKT1
32
Pathways in cancer 36
12.75 TP53 PTEN PIK3CA NOTCH1 KRAS KIT
33
Glioma 36
Show member pathways
 12.73 TP53 PTEN PIK3CA NOTCH1 KRAS HRAS
34
T cell receptor signaling pathway 36
Show member pathways
 12.7 PTEN PIK3CA KRAS HRAS AKT1
35
Immune response IL-23 signaling pathway 23
Show member pathways
 12.7 TP53 PIK3CA KRAS HRAS ERBB2 AKT1
36
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.69 PTEN PIK3CA KRAS HRAS AKT1
37
ErbB signaling pathway 36 1
Show member pathways
 12.65 TP53 PTEN PIK3CA KRAS HRAS ERBB2
38
VEGF Signaling 66
Show member pathways
 12.6 TP53 PTEN PIK3CA KRAS HRAS AKT1
39
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.6 TP53 PTEN PIK3CA KRAS HRAS ERBB2
40
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.57 PTEN PIK3CA KRAS HRAS AKT1
41
Prolactin Signaling Pathway 1 36
Show member pathways
 12.56 PTEN PIK3CA KRAS HRAS ERBB2 CREBBP
42
Apoptosis Pathway 70
Show member pathways
 12.55 TP53 PIK3CA KRAS HRAS ERBB2 AKT1
43
MicroRNAs in cancer 36
12.55 TP53 PTEN PIK3CA NOTCH1 KRAS HRAS
44
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.52 PTEN PIK3CA KRAS HRAS AKT1
45
Phospholipase D signaling pathway 36
Show member pathways
 12.52 PIK3CA KRAS KIT HRAS AKT1
46
Gastric cancer 36
Show member pathways
 12.52 TP53 PTEN PIK3CA NOTCH1 KRAS KIT
47
Development IGF-1 receptor signaling 23
Show member pathways
 12.5 TP53 PTEN PIK3CA HRAS AKT1
48
JAK-STAT signaling pathway 36
Show member pathways
 12.49 PIK3CA HRAS CREBBP AKT1
49
Development FGFR signaling pathway 23
Show member pathways
 12.49 PIK3CA KRAS HRAS AKT1
50
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.48 PIK3CA KRAS HRAS AKT1
Sources

GO Terms for Adenoid Cystic Carcinoma

About this section

Cellular components related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 TP53 PTEN PIK3CA NOTCH1 MYB KRT7
2 nucleus GO:0005634 9.83 TP53 SF3B1 PTEN NOTCH1 NFIB MYBL1
3 nucleoplasm GO:0005654 9.44 TP53 SF3B1 PTEN NOTCH1 NFIB MYBL1
4 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 9.43 KRAS CYLD AKT1

Biological processes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.06 TP53 NOTCH1 NFIB MYBL1 MYB HRAS
2 positive regulation of transcription, DNA-templated GO:0045893 9.91 TP53 NOTCH1 NFIB MYBL1 MYB CREBBP
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.9 PTEN NOTCH1 HRAS FBXW7
4 negative regulation of gene expression GO:0010629 9.89 TP53 NOTCH1 HRAS FBXW7 AKT1
5 positive regulation of protein phosphorylation GO:0001934 9.88 KRAS HRAS ERBB2 AKT1
6 cytokine-mediated signaling pathway GO:0019221 9.88 TP53 PIK3CA KRAS KIT AKT1
7 negative regulation of cell proliferation GO:0008285 9.88 TP53 PTEN NOTCH1 NFIB HRAS ARID2
8 heart development GO:0007507 9.83 TP53 PTEN NOTCH1 ERBB2 BCOR
9 Ras protein signal transduction GO:0007265 9.79 TP53 KRAS HRAS
10 positive regulation of epithelial cell proliferation GO:0050679 9.74 NOTCH1 HRAS ERBB2
11 cellular response to UV GO:0034644 9.73 TP53 FBXW7 CREBBP
12 positive regulation of Notch signaling pathway GO:0045747 9.71 NOTCH1 KIT CREBBP
13 positive regulation of cell proliferation GO:0008284 9.7 PTEN NOTCH1 KRAS KIT HRAS ERBB2
14 protein kinase B signaling GO:0043491 9.69 PTEN PIK3CA AKT1
15 anoikis GO:0043276 9.63 PIK3CA AKT1
16 homeostatic process GO:0042592 9.62 CREBBP ARID2
17 negative regulation of cell size GO:0045792 9.62 PTEN AKT1
18 liver development GO:0001889 9.62 PIK3CA NOTCH1 KRAS HRAS
19 somatic stem cell division GO:0048103 9.61 NOTCH1 KIT
20 coronary artery morphogenesis GO:0060982 9.59 NOTCH1 ARID2
21 response to isolation stress GO:0035900 9.58 KRAS HRAS
22 positive regulation of MAP kinase activity GO:0043406 9.56 KRAS KIT HRAS ERBB2
23 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.55 TP53 NOTCH1
24 cellular response to decreased oxygen levels GO:0036294 9.52 PTEN AKT1
25 phosphatidylinositol 3-kinase signaling GO:0014065 9.26 PTEN PIK3CA ERBB2 AKT1
26 positive regulation of gene expression GO:0010628 9.23 TP53 PTEN NOTCH1 KRAS KIT HRAS

Molecular functions related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 TP53 PTEN NOTCH1 KRAS IDH1 FBXW7
Sources

Sources for Adenoid Cystic Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
42